Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis.
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Feb 2019
06 Feb 2019
Historique:
received:
22
03
2018
accepted:
28
01
2019
entrez:
8
2
2019
pubmed:
8
2
2019
medline:
31
8
2019
Statut:
epublish
Résumé
The prognostic value of Ki-67 expression in colorectal cancer patients was controversial. Therefore, this meta analysis was conducted to ascertain the prognostic value of Ki-67 expression in colorectal cancer patients. The electronic databases, including EMBASE, PubMed, Cochrane Library and Web of Knowledge database, were searched from January 1970 to July 2017. The pooled hazard ratios and 95% confidence intervals were calculated to evaluate the prognostic value of Ki-67 expression for colorectal cancer patients. Totally 34 eligible studies and 6180 colorectal cancer patients were included in the present meta analysis. The pooled hazard ratios were 1.54(95% CI 1.17-2.02, P = 0.005) for overall survival and 1.43(1.12-1.83, P = 0.008) for disease free survival in univariate analysis. After adjustment of other prognostic factors, the pooled HR was 1.50(95% CI 1.02-2.22, P = 0.03) for overall survival in multivariate analysis. The present meta analysis demonstrated that high Ki-67 expression is significantly correlated with poor overall survival and disease free survival, indicating that high Ki-67 expression may serve as a valuable predictive method for poor prognosis of colorectal cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
The prognostic value of Ki-67 expression in colorectal cancer patients was controversial. Therefore, this meta analysis was conducted to ascertain the prognostic value of Ki-67 expression in colorectal cancer patients.
METHODS
METHODS
The electronic databases, including EMBASE, PubMed, Cochrane Library and Web of Knowledge database, were searched from January 1970 to July 2017. The pooled hazard ratios and 95% confidence intervals were calculated to evaluate the prognostic value of Ki-67 expression for colorectal cancer patients.
RESULTS
RESULTS
Totally 34 eligible studies and 6180 colorectal cancer patients were included in the present meta analysis. The pooled hazard ratios were 1.54(95% CI 1.17-2.02, P = 0.005) for overall survival and 1.43(1.12-1.83, P = 0.008) for disease free survival in univariate analysis. After adjustment of other prognostic factors, the pooled HR was 1.50(95% CI 1.02-2.22, P = 0.03) for overall survival in multivariate analysis.
CONCLUSION
CONCLUSIONS
The present meta analysis demonstrated that high Ki-67 expression is significantly correlated with poor overall survival and disease free survival, indicating that high Ki-67 expression may serve as a valuable predictive method for poor prognosis of colorectal cancer patients.
Identifiants
pubmed: 30727976
doi: 10.1186/s12885-019-5324-y
pii: 10.1186/s12885-019-5324-y
pmc: PMC6364416
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Subventions
Organisme : Health Department and Finance Department of Guangdong Province
ID : A2016450
Références
Int J Cancer. 1999 Jun 21;84(3):225-33
pubmed: 10371338
JAMA. 1999 Oct 6;282(13):1254-7
pubmed: 10517428
Int J Cancer. 1999 Dec 22;84(6):545-52
pubmed: 10567896
Int J Oncol. 2000 Jan;16(1):55-64
pubmed: 10601549
Clin Cancer Res. 1999 Dec;5(12):4111-8
pubmed: 10632348
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Oncology. 2001;60(2):162-9
pubmed: 11244332
Am J Surg. 2001 Jul;182(1):81-8
pubmed: 11532423
Anticancer Res. 2003 Jan-Feb;23(1A):85-9
pubmed: 12680198
Dig Dis Sci. 2003 Oct;48(10):1990-7
pubmed: 14627346
Br J Cancer. 2003 Dec 1;89(11):2093-7
pubmed: 14647143
J Clin Oncol. 2004 May 1;22(9):1572-82
pubmed: 15117979
J Urol. 2004 Jun;171(6 Pt 1):2461-6
pubmed: 15126876
J Clin Oncol. 2004 Jun 1;22(11):2133-40
pubmed: 15169799
Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):111-21
pubmed: 15354735
BMC Gastroenterol. 2004 Sep 23;4:22
pubmed: 15385053
Tumour Biol. 2004 Sep-Dec;25(5-6):258-63
pubmed: 15627889
World J Gastroenterol. 2005 Jun 7;11(21):3245-9
pubmed: 15929175
Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1455-61
pubmed: 17445998
Clin Transl Oncol. 2007 Oct;9(10):663-70
pubmed: 17974527
J Clin Epidemiol. 2008 Oct;61(10):991-6
pubmed: 18538991
Br J Cancer. 2008 Nov 18;99(10):1712-7
pubmed: 18985041
Ai Zheng. 2008 Dec;27(12):1321-6
pubmed: 19080002
Eur J Cancer. 2009 May;45(8):1466-73
pubmed: 19223178
Dis Colon Rectum. 2009 Feb;52(2):319-26
pubmed: 19279430
Oncol Rep. 2009 May;21(5):1189-95
pubmed: 19360293
Dig Dis Sci. 2010 Apr;55(4):1098-105
pubmed: 19399614
Ann Surg Oncol. 2009 Dec;16(12):3499-506
pubmed: 19672661
Ann Surg Oncol. 2010 Feb;17(2):572-8
pubmed: 19727962
J Cancer Res Clin Oncol. 2010 Jul;136(7):997-1006
pubmed: 20024662
Hepatogastroenterology. 2010 Jul-Aug;57(101):734-40
pubmed: 21033219
J Clin Pathol. 2011 Jun;64(6):498-503
pubmed: 21415057
Ann Surg Oncol. 2011 Jul;18(7):2074-83
pubmed: 21442350
J Clin Pathol. 2012 Nov;65(11):989-95
pubmed: 22859394
World J Surg Oncol. 2012 Nov 15;10:244
pubmed: 23153436
HPB (Oxford). 2014 Mar;16(3):235-42
pubmed: 23509992
Br J Cancer. 2013 Oct 15;109(8):2207-16
pubmed: 24022192
Histopathology. 2014 Mar;64(4):577-84
pubmed: 24111856
Gut Liver. 2014 Jan;8(1):13-23
pubmed: 24516696
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Exp Clin Cancer Res. 2015 May 20;34:51
pubmed: 25986235
Am J Cancer Res. 2015 Feb 15;5(3):1225-33
pubmed: 26046001
J Cell Biol. 1993 Nov;123(3):513-22
pubmed: 8227122